An influencing factor to predict plasma valproate concentrations

Circadian stage-dependent kinetics

Shigehiro Ohdo, Shigeyuki Nakano, Nobuya Ogawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study was designed to examine how the dosing time of the day influenced the accuracy in predicting plasma valproate (VPA) concentrations at steady state. Eight healthy male volunteers took 400-mg doses of VPA for 9 days on a twice-daily basis (08: 30 and 20 : 30). The circadian changes in VPA kinetics occurred at the absorption phase. The prediction of plasma VPA concentrations at 2hr (around Cmax) and at 12hr after both the morning and the evening dose on the ninth day was performed using the individual subject's pharmacokinetic parameters and population pharmacokinetic parameters (Bayesian method) obtained from the morning trial on the eighth day. The predictive accuracy for VPA concentration around Cmaxafter the morning dose was better, but that for VPA concentration after the evening dose was significantly biased toward overestimation. The individual pharmacokinetic parameters obtained from the morning trial became better sources for the prediction of VPA concentrations around Cmax after the morning dose, but worse sources for that after the evening dose. The predictive performance based on the Bayesian approach also showed the similar finding to that based on individual pharmacokinetic parameters. The overestimation of the target points around Cmaxafter the evening dose is closely related to that of Kavalue produced by using population parameters obtained from morning trial. Therefore, these results suggest that the time in the circadian stage at which VPA is administered is important for evaluating exactly the predictive accuracy.

Original languageEnglish
Pages (from-to)747-754
Number of pages8
JournalRinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Volume21
Issue number4
DOIs
Publication statusPublished - Jan 1 1990
Externally publishedYes

Fingerprint

Valproic Acid
Pharmacokinetics
Bayes Theorem
Population
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

An influencing factor to predict plasma valproate concentrations : Circadian stage-dependent kinetics. / Ohdo, Shigehiro; Nakano, Shigeyuki; Ogawa, Nobuya.

In: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 21, No. 4, 01.01.1990, p. 747-754.

Research output: Contribution to journalArticle

@article{3048b4c7ad514de2acbf2bba28fd8a49,
title = "An influencing factor to predict plasma valproate concentrations: Circadian stage-dependent kinetics",
abstract = "This study was designed to examine how the dosing time of the day influenced the accuracy in predicting plasma valproate (VPA) concentrations at steady state. Eight healthy male volunteers took 400-mg doses of VPA for 9 days on a twice-daily basis (08: 30 and 20 : 30). The circadian changes in VPA kinetics occurred at the absorption phase. The prediction of plasma VPA concentrations at 2hr (around Cmax) and at 12hr after both the morning and the evening dose on the ninth day was performed using the individual subject's pharmacokinetic parameters and population pharmacokinetic parameters (Bayesian method) obtained from the morning trial on the eighth day. The predictive accuracy for VPA concentration around Cmaxafter the morning dose was better, but that for VPA concentration after the evening dose was significantly biased toward overestimation. The individual pharmacokinetic parameters obtained from the morning trial became better sources for the prediction of VPA concentrations around Cmax after the morning dose, but worse sources for that after the evening dose. The predictive performance based on the Bayesian approach also showed the similar finding to that based on individual pharmacokinetic parameters. The overestimation of the target points around Cmaxafter the evening dose is closely related to that of Kavalue produced by using population parameters obtained from morning trial. Therefore, these results suggest that the time in the circadian stage at which VPA is administered is important for evaluating exactly the predictive accuracy.",
author = "Shigehiro Ohdo and Shigeyuki Nakano and Nobuya Ogawa",
year = "1990",
month = "1",
day = "1",
doi = "10.3999/jscpt.21.747",
language = "English",
volume = "21",
pages = "747--754",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - An influencing factor to predict plasma valproate concentrations

T2 - Circadian stage-dependent kinetics

AU - Ohdo, Shigehiro

AU - Nakano, Shigeyuki

AU - Ogawa, Nobuya

PY - 1990/1/1

Y1 - 1990/1/1

N2 - This study was designed to examine how the dosing time of the day influenced the accuracy in predicting plasma valproate (VPA) concentrations at steady state. Eight healthy male volunteers took 400-mg doses of VPA for 9 days on a twice-daily basis (08: 30 and 20 : 30). The circadian changes in VPA kinetics occurred at the absorption phase. The prediction of plasma VPA concentrations at 2hr (around Cmax) and at 12hr after both the morning and the evening dose on the ninth day was performed using the individual subject's pharmacokinetic parameters and population pharmacokinetic parameters (Bayesian method) obtained from the morning trial on the eighth day. The predictive accuracy for VPA concentration around Cmaxafter the morning dose was better, but that for VPA concentration after the evening dose was significantly biased toward overestimation. The individual pharmacokinetic parameters obtained from the morning trial became better sources for the prediction of VPA concentrations around Cmax after the morning dose, but worse sources for that after the evening dose. The predictive performance based on the Bayesian approach also showed the similar finding to that based on individual pharmacokinetic parameters. The overestimation of the target points around Cmaxafter the evening dose is closely related to that of Kavalue produced by using population parameters obtained from morning trial. Therefore, these results suggest that the time in the circadian stage at which VPA is administered is important for evaluating exactly the predictive accuracy.

AB - This study was designed to examine how the dosing time of the day influenced the accuracy in predicting plasma valproate (VPA) concentrations at steady state. Eight healthy male volunteers took 400-mg doses of VPA for 9 days on a twice-daily basis (08: 30 and 20 : 30). The circadian changes in VPA kinetics occurred at the absorption phase. The prediction of plasma VPA concentrations at 2hr (around Cmax) and at 12hr after both the morning and the evening dose on the ninth day was performed using the individual subject's pharmacokinetic parameters and population pharmacokinetic parameters (Bayesian method) obtained from the morning trial on the eighth day. The predictive accuracy for VPA concentration around Cmaxafter the morning dose was better, but that for VPA concentration after the evening dose was significantly biased toward overestimation. The individual pharmacokinetic parameters obtained from the morning trial became better sources for the prediction of VPA concentrations around Cmax after the morning dose, but worse sources for that after the evening dose. The predictive performance based on the Bayesian approach also showed the similar finding to that based on individual pharmacokinetic parameters. The overestimation of the target points around Cmaxafter the evening dose is closely related to that of Kavalue produced by using population parameters obtained from morning trial. Therefore, these results suggest that the time in the circadian stage at which VPA is administered is important for evaluating exactly the predictive accuracy.

UR - http://www.scopus.com/inward/record.url?scp=0025677311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025677311&partnerID=8YFLogxK

U2 - 10.3999/jscpt.21.747

DO - 10.3999/jscpt.21.747

M3 - Article

VL - 21

SP - 747

EP - 754

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -